Johnson & Johnson (JNJ.N)
A federal judge in Illinois has rejected Johnson & Johnson's bid to transfer a lawsuit alleging its talc products caused a woman's ovarian cancer to federal from state court.
Johnson & Johnson reported slightly better-than-expected third quarter profit and raised its full-year forecast on Tuesday as increased demand for cancer drugs and immune disorder treatments powered strong results for its pharmaceutical unit.
Johnson & Johnson applauded a U.S. government proposal requiring drugmakers to include price of medicines in television ads, Chief Financial Officer Joseph Wolk said in a CNBC interview on Tuesday.
* Sees device unit growing in-line or better than market by 2020 (Adds details from conference call, share move)
Oct 16 Johnson & Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade.
Oct 16 Johnson & Johnson reported a 4.5 percent rise in quarterly profit on Tuesday and boosted its sales and earnings per share guidance, as rising sales of its cancer drugs Zytiga and Darzalex helped offset falling sales of blockbuster arthritis drug Remicade.
A New Jersey jury on Thursday cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer.
Oct 11 A New Jersey jury on Thursday cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer.
Johnson & Johnson unit Acclarent Inc says that a former sales representative cannot prove she was fired because she complained to her bosses about the company's promotion of a medical device for unapproved uses, rather than her poor performance.
Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.
|General Electric Company (GE.N)||$12.56||+0.18|
|Procter & Gamble Co (PG.N)||$87.30||+7.06|
|Pfizer Inc. (PFE.N)||$44.50||+0.50|
|Novartis AG (NOVN.S)||CHF87.04||+1.16|
|Merck & Co., Inc. (MRK.N)||$72.35||+0.14|
|Baxter International Inc (BAX.N)||$69.46||-1.01|
|Stryker Corporation (SYK.N)||$168.94||-4.16|
|Boston Scientific Corporation (BSX.N)||$36.54||-0.99|
|Zimmer Biomet Holdings Inc (ZBH.N)||$124.40||-1.92|